Late-stage study underway for Resverlogix's lead product candidate for CV disease

Nov 11 2015, 12:03 ET | About: Resverlogix Corp. (RVXCF) | By: Douglas W. House, SA News Editor Contact this editor with comments or a news tip

• Resverlogix (OTCPK:RVXCF) announces that the first patient has been dosed in its Phase 3 clinical trial, BETonMACE, assessing lead product candidate apabetalone (RVX-208) in high-risk patients with coronary artery disease (CAD) and type 2 diabetes. The primary endpoint is the effect of apabetalone on time to first occurrence of Major Cardiovascular Events (MACE) in the targeted population. MACE is a single composite endpoint that includes cardiovascular death or non-fatal myocardial infarction (heat attack) or stroke. All study participants will remain on high-dose statin therapy [Lipitor (atorvastatin) or Crestor (rosuvastatin)] with the test group receiving 200 mg/day of apabetalone (two 100 mg capsules per day).
• According to clinicaltrials.gov, the estimated final data collection date for the primary endpoint is September 2018. The estimated study completion date is October 2018.
• Apabetalone works via an epigenetic mechanism called BET (bromodomain and extra-terminal) inhibition which regulates disease-causing genes. It specifically inhibits the second bromodomain (BD2) within the BET protein called BRD4, thereby producing a potential treatment benefit in patients with CV disease, diabetes, chronic kidney disease, Alzheimer's and other conditions.